James A. Orsini1, Lawrence R. Soma1, James E. Rourke1, M. Park2
1*University of Pennsylvania, School of Veterinary Medicine, New Bolton Center Campus, Kennett Square, Philadelphia, and †Bristol Laboratories, Syracuse, New York, U.S.A
2‡8323 Beverly Drive, San Gabriel, CA 91775, U.S.A
Tóm tắt
Orsini, J.A., Soma, L.R., Rourke, J.E. & Park M. Pharmacokinetics of amikacin in the horse following intravenous and intræmuscular administration. J. vet. Pharmacol. Therap. 8, 194–201.The pharmacokinetics of amikacin sulfate (AK) were studied in the horse after intravenous (i.v.) and intramuscular (i.m.) administration. Serum (Cs), synovial (Csf) and peritoneal (Cpf) fluid concentrations of the drug were measured. Doses of 4.4, 6.6 and 11.0 mg/kg were given. The concentrations at 15 min following i.v. injection were 30.3 ± 0.3, 61.2 ± 6.9 and 122.8 ± 7.4 (μg/ml, respectively, for the 4.4, 6.6 and 11.0 mg/kg doses. Mean peak Cs values after the intramuscular injections occurred at 1.0 h post‐injection and were 13.3 ± 1.6, 23.0 ± 0.6 and 29.8 ± 3.2 μg/ml, respectively. The t1/2 of amikacin was 1.44, 1.57 and 1.14 h for the 4.4, 6.6 and 11.0 mg/kg doses, respectively. In this study, minimum inhibitory concentrations (MIC) of amikacin sulfate were determined for six pathogens. Based on the MIC and the pharmacokinetic parameters, it would appear that the usual therapeutic dose of amikacin would be between 4.4 and 6.6 mg/kg twice daily and, for the more serious life‐threatening infections, dosing three times a day. J. A. Orsini, University of Pennsylvania, School of Veterinary Medicine, New Bolton Center Campus, Kennett Square, PA 19348, U.S.A.
